BR112018011862A2 - moléculas de anticorpo que ligam tnf alfa - Google Patents

moléculas de anticorpo que ligam tnf alfa

Info

Publication number
BR112018011862A2
BR112018011862A2 BR112018011862A BR112018011862A BR112018011862A2 BR 112018011862 A2 BR112018011862 A2 BR 112018011862A2 BR 112018011862 A BR112018011862 A BR 112018011862A BR 112018011862 A BR112018011862 A BR 112018011862A BR 112018011862 A2 BR112018011862 A2 BR 112018011862A2
Authority
BR
Brazil
Prior art keywords
antibody molecules
bind alpha
alpha tnf
tnf
bind
Prior art date
Application number
BR112018011862A
Other languages
English (en)
Inventor
John Lightwood Daniel
Paul Humphreys David
Marshall Diane
Dave Emma
Bhatta Pallavi
Adams Ralph
Philip Heywood Sam
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112018011862A2 publication Critical patent/BR112018011862A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a invenção se refere às moléculas de anticorpo tendo especificidade para tnf alfa, usos terapêuticos das moléculas de anticorpo e métodos para produzir as ditas moléculas de anticorpo.
BR112018011862A 2015-12-18 2016-12-14 moléculas de anticorpo que ligam tnf alfa BR112018011862A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522394.4A GB201522394D0 (en) 2015-12-18 2015-12-18 Antibodies
PCT/EP2016/080984 WO2017102833A1 (en) 2015-12-18 2016-12-14 Antibody molecules which bind tnf alpha

Publications (1)

Publication Number Publication Date
BR112018011862A2 true BR112018011862A2 (pt) 2018-12-04

Family

ID=55311230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011862A BR112018011862A2 (pt) 2015-12-18 2016-12-14 moléculas de anticorpo que ligam tnf alfa

Country Status (18)

Country Link
US (1) US11091542B2 (pt)
EP (1) EP3390446A1 (pt)
JP (1) JP7082053B2 (pt)
KR (1) KR20180089521A (pt)
CN (1) CN108368168B (pt)
AR (1) AR107071A1 (pt)
AU (1) AU2016374375A1 (pt)
BR (1) BR112018011862A2 (pt)
CA (1) CA3007580A1 (pt)
CL (1) CL2018001661A1 (pt)
CO (1) CO2018006555A2 (pt)
EA (1) EA036904B1 (pt)
GB (1) GB201522394D0 (pt)
IL (1) IL259883A (pt)
MX (1) MX2018007221A (pt)
RU (1) RU2018126315A (pt)
SG (1) SG11201804801SA (pt)
WO (1) WO2017102833A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144431B (zh) * 2019-08-08 2023-04-14 神州细胞工程有限公司 人源化抗TNFα抗体及其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
CN1300173C (zh) * 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2003083061A2 (en) 2002-03-26 2003-10-09 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
BR122013001996B1 (pt) * 2005-05-18 2022-02-01 Ablynx N.V. Nanocorpos melhorados contra fator alfa de necrose tumoral
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
TWI609965B (zh) * 2007-05-21 2018-01-01 艾爾德生物控股有限責任公司 新穎兔抗體人化方法以及經人化之兔抗體
WO2008144753A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
JP5751631B2 (ja) * 2008-10-31 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド Ｔｏｌｌ様受容体３アンタゴニスト
MX2011010908A (es) 2009-04-16 2012-02-21 Abbott Biotherapeutics Corp Anticuerpos anti-tnf-alfa y sus usos.
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
BR112013010857A2 (pt) 2010-11-02 2016-09-13 Abbott Laboratoires imonoglubulinas de duplo domínio variável e usos das mesmas
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013035012A2 (en) 2011-09-06 2013-03-14 Koninklijke Philips Electronics N.V. Wire-based lighting module with 3d topography
UY34409A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoenlazadores dirigidos contra el tnf
WO2013063110A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
JP6832707B2 (ja) 2014-03-26 2021-02-24 セル メディカ スイッツァランド アーゲー ＴＮＦαに対する結合メンバー
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
MX2017002765A (es) 2014-09-03 2017-10-16 Boehringer Ingelheim Int Il-23a y tnf-alfa orientados y compuesto y sus usos.
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
NO2768984T3 (pt) 2015-11-12 2018-06-09
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules

Also Published As

Publication number Publication date
GB201522394D0 (en) 2016-02-03
CN108368168B (zh) 2022-03-01
AU2016374375A1 (en) 2018-06-28
EP3390446A1 (en) 2018-10-24
WO2017102833A1 (en) 2017-06-22
MX2018007221A (es) 2018-08-01
KR20180089521A (ko) 2018-08-08
CN108368168A (zh) 2018-08-03
CA3007580A1 (en) 2017-06-22
US11091542B2 (en) 2021-08-17
AU2016374375A8 (en) 2018-07-05
CL2018001661A1 (es) 2018-10-19
US20200291104A1 (en) 2020-09-17
CO2018006555A2 (es) 2018-07-10
JP2019508367A (ja) 2019-03-28
SG11201804801SA (en) 2018-07-30
EA036904B1 (ru) 2021-01-13
IL259883A (en) 2018-07-31
JP7082053B2 (ja) 2022-06-07
RU2018126315A (ru) 2020-01-20
EA201891445A1 (ru) 2018-11-30
AR107071A1 (es) 2018-03-14
RU2018126315A3 (pt) 2020-04-30

Similar Documents

Publication Publication Date Title
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
UY37779A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CR20160347A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
EA201791485A1 (ru) Анти-cd47-антитела и их применения
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
ECSP15040888A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA TNF alfa
UY35967A (es) Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas
BR112018011860A2 (pt) moléculas de anticorpo multi-específicas tendo especificidade para tnf-alfa, il-17a e il-17f
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
BR112017012515A2 (pt) membros vinculantes para c-maf humano
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
BR112018011862A2 (pt) moléculas de anticorpo que ligam tnf alfa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)